menu
    • menu
    [{"orgOrder":0,"company":"Axoltis","sponsor":"ACT4ALS network","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"NX210c","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Axoltis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axoltis \/ ACT4ALS network","highestDevelopmentStatusID":"8","companyTruncated":"Axoltis \/ ACT4ALS network"},{"orgOrder":0,"company":"Axoltis","sponsor":"Centre for Human Drug Research","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"NX210c","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Axoltis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axoltis \/ Centre for Human Drug Research","highestDevelopmentStatusID":"6","companyTruncated":"Axoltis \/ Centre for Human Drug Research"}]

    Find Clinical Drug Pipeline Developments & Deals by Axoltis

    Menu

    Axoltis

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Axoltis

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Axoltis

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NX210c

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : ACT4ALS network

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ALS Phase II Study of NX210c

                            Details : NX210c is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            April 15, 2024

                            Lead Product(s) : NX210c

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : ACT4ALS network

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Axoltis

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Axoltis

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NX210c

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Centre for Human Drug Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MAD Study of NX210c

                            Details : NX210c is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            April 25, 2023

                            Lead Product(s) : NX210c

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Centre for Human Drug Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth